Edgar Filing: GILEAD SCIENCES INC - Form 4

GILEAD SCIEN Form 4 January 24, 2007										
FORM 4	UNITED	UNITED STATES SECURITIES AND EXCHANGE Washington, D.C. 20549						N OMB Number:	PPROVAL 3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5 obligations	Filed pur	STATEMENT OF CHANG S Filed pursuant to Section 16(Section 17(a) of the Public Utili				ties Excha	Estimated burden hou response	2005 average urs per		
may continue <i>See</i> Instructio 1(b).	•			•	•	ny Act of 1				
(Print or Type Resp	onses)									
1. Name and Addre YANG TAIYIN	Person <u>*</u>	2. Issue Symbol	er Name an	d Ticker or	r Trading	5. Relationship of Reporting Person(s) to Issuer				
		GILEA	D SCIEN	ICES IN	C [GILD]	(Check all applicable)				
(Last) (First) (Middle) GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 01/22/2007				Director 10% Owner X_ Officer (give title Other (specify below) below) SVP, Pharm Dev & Mfg			
				4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
FOSTER CITY	, CA 94404						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
	ransaction Date nth/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Report of	on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
							spond to the colle tained in this form		SEC 1474 (9-02)	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securit
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: GILEAD SCIENCES INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)		Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 65.58	01/22/2007		А		40,000		<u>(1)</u>	01/22/2017	Common Stock	40,0

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
YANG TAIYIN GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404			SVP, Pharm Dev & Mfg	
Signatures				
/s/Matthew K. Au by Power of	01/24/2007			

/s/Matthew K. Au by Power of Attorney for Taryin Yang

> **Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly (1)installments over the next four years, ending on 1/22/2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.